Literature DB >> 25957963

Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.

Gary Wong1, Jason S Richardson2, Stéphane Pillet2, Trina Racine2, Ami Patel1, Geoff Soule2, Jane Ennis3, Jeffrey Turner3, Xiangguo Qiu1, Gary P Kobinger4.   

Abstract

Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Ebola; adenovirus; nonhuman primates; post-exposure; vaccine

Mesh：

Substances：

Year:  2015        PMID： 25957963      PMCID： PMC4564535          DOI： 10.1093/infdis/jiv102

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  12 in total

1.  Ebola by the numbers: The size, spread and cost of an outbreak.

Authors:  Declan Butler; Lauren Morello
Journal:  Nature       Date:  2014-10-16       Impact factor: 49.962

Review 2.  Post-exposure therapy of filovirus infections.

Authors:  Gary Wong; Xiangguo Qiu; Gene G Olinger; Gary P Kobinger
Journal:  Trends Microbiol       Date:  2014-04-30       Impact factor: 17.079

Review 3.  Ebola virus vaccines: an overview of current approaches.

Authors:  Andrea Marzi; Heinz Feldmann
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

4.  Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.

Authors:  Jason S Richardson; Gary Wong; Stéphane Pillet; Samantha Schindle; Jane Ennis; Jeffrey Turner; James E Strong; Gary P Kobinger
Journal:  J Bioterror Biodef       Date:  2011-10-20

5.  Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.

Authors:  Gary Wong; Jason S Richardson; Stéphane Pillet; Ami Patel; Xiangguo Qiu; Judie Alimonti; Jeff Hogan; Yi Zhang; Ayato Takada; Heinz Feldmann; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2012-10-31       Impact factor: 17.956

6.  Antibody-dependent enhancement of Ebola virus infection.

Authors:  Ayato Takada; Heinz Feldmann; Thomas G Ksiazek; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Effective post-exposure treatment of Ebola infection.

Authors:  Heinz Feldmann; Steven M Jones; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Ute Ströher; Allen Grolla; Mike Bray; Elizabeth A Fritz; Lisa Fernando; Friederike Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS Pathog       Date:  2007-01       Impact factor: 6.823

8.  A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.

Authors:  Jin Huk Choi; Kristina Jonsson-Schmunk; Xiangguo Qiu; Devon J Shedlock; Jim Strong; Jason X Xu; Kelly L Michie; Jonathan Audet; Lisa Fernando; Mark J Myers; David Weiner; Irnela Bajrovic; Lilian Q Tran; Gary Wong; Alexander Bello; Gary P Kobinger; Stephen C Schafer; Maria A Croyle
Journal:  Mol Pharm       Date:  2014-11-14       Impact factor: 4.939

9.  Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Authors:  Jason S Richardson; Michel K Yao; Kaylie N Tran; Maria A Croyle; James E Strong; Heinz Feldmann; Gary P Kobinger
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962
View more
  11 in total

Review 1.  Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Authors:  Gary Wong; Gary P Kobinger
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 2.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Authors:  Gary Wong; Emelissa J Mendoza; Francis A Plummer; George F Gao; Gary P Kobinger; Xiangguo Qiu
Journal:  Expert Opin Biol Ther       Date:  2017-11-17       Impact factor: 4.388

3.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

Review 4.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

Review 5.  Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.

Authors:  James Logue; Ian Crozier; Peter B Jahrling; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2020-01-30       Impact factor: 5.683

6.  Prognostic Analysis of Patients with Ebola Virus Disease.

Authors:  Xin Zhang; Yihui Rong; Lijian Sun; Liming Liu; Haibin Su; Jian Zhang; Guangju Teng; Ning Du; Haoyang Chen; Yuan Fang; Wei Zhan; Alex B J Kanu; Sheku M Koroma; Bo Jin; Zhe Xu; Haihan Song
Journal:  PLoS Negl Trop Dis       Date:  2015-09-23

Review 7.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

8.  Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.

Authors:  Mable Hagan; Charlene Ranadheera; Jonathan Audet; Jocelyn Morin; Anders Leung; Darwyn Kobasa
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

9.  Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.

Authors:  Stuart D Dowall; Frédéric Jacquot; John Landon; Emma Rayner; Graham Hall; Caroline Carbonnelle; Hervé Raoul; Delphine Pannetier; Ian Cameron; Ruth Coxon; Ibrahim Al Abdulla; Roger Hewson; Miles W Carroll
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.